Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Survival in Patients with High-Risk Prostate Cancer Is Predicted by miR-221, Which Regulates Proliferation, Apoptosis, and Invasion of Prostate Cancer Cells by Inhibiting IRF2 and SOCS3

(2014) B. Kneitz et al.   CANCER RESEARCH

miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases

(2013) Ernest K Amankwah et al.   ASIAN JOURNAL OF ANDROLOGY

Circulating microRNAs predict biochemical recurrence in prostate cancer patients

(2013) L A Selth et al.   BRITISH JOURNAL OF CANCER

MicroRNA Signature Helps Distinguish Early from Late Biochemical Failure in Prostate Cancer

(2013) Z. Lichner et al.   CLINICAL CHEMISTRY

Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer

(2013) S Mishra et al.   ONCOGENE

Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network

(2013) Medha Darshan et al.   PROSTATE

Do microRNA 96, 145 and 221 expressions really aid in the prognosis of prostate carcinoma?

(2012) Sung Gu Kang et al.   ASIAN JOURNAL OF ANDROLOGY

Variation in IL10 and Other Genes Involved in the Immune Response and in Oxidation and Prostate Cancer Recurrence

(2012) P. J. Dluzniewski et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

miR-21 as an Independent Biochemical Recurrence Predictor and Potential Therapeutic Target for Prostate Cancer

(2012) Tao Li et al.   JOURNAL OF UROLOGY

Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer

(2012) Alcides Chaux et al.   MODERN PATHOLOGY

The microcosmos of cancer

(2012) Amaia Lujambio et al.   NATURE

Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome

(2012) P. J. Hurley et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer

(2012) Han Christine Ngoc Nguyen et al.   PROSTATE

MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer

(2011) Jelena Radojicic et al.   CELL CYCLE

Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease

(2011) Luke A. Selth et al.   INTERNATIONAL JOURNAL OF CANCER

Active Surveillance for Prostate Cancer: Progress and Promise

(2011) Matthew R. Cooperberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased gene copy number of ERG on chromosome 21 but not TMPRSS2–ERG fusion predicts outcome in prostatic adenocarcinomas

(2011) Antoun Toubaji et al.   MODERN PATHOLOGY

Genomics and the Continuum of Cancer Care

(2011) Ultan McDermott et al.   NEW ENGLAND JOURNAL OF MEDICINE

MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4

(2011) K Schramedei et al.   ONCOGENE

The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer

(2011) Tong Sun et al.   PROSTATE

Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer

(2011) Fulya Yaman Agaoglu et al.   TUMOR BIOLOGY

Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells

(2010) Guo-hai Shi et al.   ACTA PHARMACOLOGICA SINICA

Regulation of mRNA Translation and Stability by microRNAs

(2010) Marc Robert Fabian et al.   Annual Review of Biochemistry

Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21

(2010) Mark E. Hatley et al.   CANCER CELL

Microfluidic-Based Multiplex qRT-PCR Identifies Diagnostic and Prognostic microRNA Signatures in the Sera of Prostate Cancer Patients

(2010) Felix Moltzahn et al.   CANCER RESEARCH

Decreased Expression of Cyr61 Is Associated with Prostate Cancer Recurrence after Surgical Treatment

(2010) K. B. D'Antonio et al.   CLINICAL CANCER RESEARCH

Circulating miRNAs are correlated with tumor progression in prostate cancer

(2010) Jan C. Brase et al.   INTERNATIONAL JOURNAL OF CANCER

OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma

(2010) Pedro P. Medina et al.   NATURE

Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy

(2010) Hai-Liang Zhang et al.   PROSTATE

MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells

(2009) Tao Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A Simulation Study of Control Sampling Methods for Nested Case-Control Studies of Genetic and Molecular Biomarkers and Prostate Cancer Progression

(2009) M.-H. Wang et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

miR-21: An Androgen Receptor-Regulated MicroRNA that Promotes Hormone-Dependent and Hormone-Independent Prostate Cancer Growth

(2009) J. Ribas et al.   CANCER RESEARCH

Genomic Profiling of MicroRNA and Messenger RNA Reveals Deregulated MicroRNA Expression in Prostate Cancer

(2008) S. Ambs et al.   CANCER RESEARCH

miR-21: a small multi-faceted RNA

(2008) Anna M. Krichevsky et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Circulating microRNAs as stable blood-based markers for cancer detection

(2008) P. S. Mitchell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA